Liraglutide and Weight Loss Among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. Methods and results: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’ analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a significant weight reduction [liraglutide −1.00 lbs vs. placebo 2.00 lbs; treatment difference −4.10 lbs; 95% confidence interval (CI) −7.94, −0.25; P = 0.0367; percentage treatment difference −2.07%, 95% CI −3.86, −0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference −33.1 mg/dL; 95% CI −60.7, −5.6; P = 0.019). Conclusions: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“59 Hyperglycaemic event 16% (39) 12% (15) 19% (24) 0.”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 3×
“0) Ischaemic HF aetiology* % (n) 75% (93) 88% (108) 81% (201) Hypertension % (n) 75% (93) 80% (97) 77% (190) History of atrial fibrillation % (n) 46% (57) 47% (57) 47% (114) Diabetes % (n) 60% (75) 56% (69) 58% (144) Chronic renal insufficiency* % (n) 31% (39) 45% (54) 38% (93) Beta-blocker use % (n) 94% (117) 93% (11…”
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · cited 2×
“2) NYHA Class I 2% (2) 2% (2) 2% (4) II 26% (31) 30% (36) 28% (67) III 70% (84) 64% (78) 66% (162) IV 3% (3) 5% (6) 4% (9) KCCQ overall summary score 40.”
Self-citationJorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“12 Any serious adverse event through Day 180 19% (47) 17% (21) 21% (26) 0.”
Research works printed but not linked: 15
- Horwich, 2011, Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure, Am J Cardiol, 108, 1754, 10.1016/j.amjcard.2011.07.051 · DOI · Paper page
- Joyce, 2016, Prevalence, profile, and prognosis of severe obesity in contemporary hospitalized heart failure trial populations, JACC Heart Fail, 4, 923, 10.1016/j.jchf.2016.09.013 · DOI · Paper page
- Margulies, 2014, GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study, Circ Heart Fail, 7, 673, 10.1161/CIRCHEARTFAILURE.114.000346 · DOI · Paper page
- Lala, 2015, Relief and recurrence of congestion during and after hospitalization for acute heart failure, Circ Heart Fail, 8, 741, 10.1161/CIRCHEARTFAILURE.114.001957 · DOI · Paper page
- Cefalu, 2015, Standards of medical care in diabetes, Diabetes Care, 38, 1177, 10.2337/dc15-0875 · DOI
- Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019 · DOI · Paper page
- Sharma, 2017, A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure, Eur J Heart Fail, 19, 1310, 10.1002/ejhf.912 · DOI
- Sharma, 2016, Heart failure event definitions in drug trials in patients with type 2 diabetes, Lancet Diabetes Endocrinol, 4, 294, 10.1016/S2213-8587(16)00049-8 · DOI
- Carbone, 2016, Lack of benefit for liraglutide in heart failure, JAMA, 316, 2429, 10.1001/jama.2016.15387 · DOI
- Margulies, 2016, Lack of benefit for liraglutide in heart failure—reply, JAMA, 316, 2429, 10.1001/jama.2016.15394 · DOI
- Rossignol, 2015, Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials, Eur J Heart Fail, 17, 424, 10.1002/ejhf.240 · DOI · Paper page
- Wohlfahrt, 2014, Impact of general and central adiposity on ventricular-arterial aging in women and men, JACC Heart Fail, 2, 489, 10.1016/j.jchf.2014.03.014 · DOI · Paper page
- Borlaug, 2013, Longitudinal changes in left ventricular stiffness: a community-based study, Circ Heart Fail, 6, 944, 10.1161/CIRCHEARTFAILURE.113.000383 · DOI · Paper page
- Zamora, 2016, No benefit from the obesity paradox for diabetic patients with heart failure, Eur J Heart Fail, 18, 851, 10.1002/ejhf.576 · DOI
- Kamiya, 2016, Complementary role of arm circumference to body mass index in risk stratification in heart failure, JACC Heart Fail, 4, 265, 10.1016/j.jchf.2015.11.010 · DOI
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., Lingvay, I., Colhoun, H. M., Plutzky, J., Kosiborod, M. N., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01498-3 · Cited by 275
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“…failure with preserved ejection fraction, whether with or without type 2 diabetes, possibly because of the beneficial effects on body weight 133,134 , whereas liraglutide was unsuccessful in dedicated studies of its effects in patients with heart failure and reduced ejection fraction 135,136 .”
GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
Malhotra, K., Katsanos, A. H., Lambadiari, V., Goyal, N., Palaiodimou, L., Kosmidou, M., Krogias, C., Alexandrov, A. V., & Tsivgoulis, G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09813-4 · Cited by 65
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Mentias, A., Desai, M. Y., Aminian, A., Patel, K. V., Keshvani, N., Verma, S., Cho, L., Jacob, M., Alvarez, P., Lincoff, A. M., et al. (2024) · Circulation: Heart Failure · doi:10.1161/circheartfailure.122.010453 · Cited by 40
Metadata
- Authors
- Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., Vader, J., Groake, J. D., Borlaug, B. A., & Velazquez, E. J.
- Venue
- ESC Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-08-17
- Volume
- 5
- Issue
- 6
- Pages
- 1035-1043
- ISSN
- 2055-5822 (ISSN-L)
- OpenAlex
- W2886598107
- Cited by
- 45
- References
- 12
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- Funders
- National Heart, Lung, and Blood Institute (U10 HL110338, U10 HL110336, U10 HL110309, U10 HL110302, U10 HL110297, U10 HL110262, U10 HL110342, U10 HL110337, U10 HL110312, U01 HL084861, U10 HL084904)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.